KR960000222A - 구강 건조증 치료제 - Google Patents

구강 건조증 치료제 Download PDF

Info

Publication number
KR960000222A
KR960000222A KR1019950015296A KR19950015296A KR960000222A KR 960000222 A KR960000222 A KR 960000222A KR 1019950015296 A KR1019950015296 A KR 1019950015296A KR 19950015296 A KR19950015296 A KR 19950015296A KR 960000222 A KR960000222 A KR 960000222A
Authority
KR
South Korea
Prior art keywords
dry mouth
acid addition
addition salt
aryl
alkyl
Prior art date
Application number
KR1019950015296A
Other languages
English (en)
Other versions
KR100322042B1 (ko
Inventor
하루미 한다
야스요시 다께야마
Original Assignee
가다야마 스미오
유끼지루시유교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가다야마 스미오, 유끼지루시유교 가부시끼가이샤 filed Critical 가다야마 스미오
Publication of KR960000222A publication Critical patent/KR960000222A/ko
Application granted granted Critical
Publication of KR100322042B1 publication Critical patent/KR100322042B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)

Abstract

하기 식(Ⅰ)로 표시되는 스피로옥사티올란퀴누클리딘 유도체 또는 그 산부가염을 유효 성분으로 하는 구강건조증 치료제.
(식중, R1및 R2는 동일하든지 다른 것이라도 좋고, 각각 수소, 알킬, 시클로벤틸, 아릴 또는 디아릴메틸롤 또는 하나 이상의 아릴기로 치환된 알킬이다.)
전기 치료제를 경구 또는 비경구적으로 투여하면 구강 건조증을 치료할 수 있다.
구체적으로는 타액선의 기질적 변화를 일으키는 각종 질환이나 전신성 질환에 수반하는 타액선의 병변, 방사선 치료에 의한 타액선 세포의 파괴, HIV감염(AIDS), 가령에 의한 분비 기능의 저하, 각종 약제의 복용에 의한 영향, 더우기는 복잡한 사회생활 조건에 대한 정신적인 피로나 부조(不調)등에 기인하는 구강 건조의 병태를 개선 또는 치료할 수가 있다.

Description

구강 건조증 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 다음 일반식(Ⅰ)로 표시되는 스피로옥사티올란퀴누클리딘 유도체 또는 그 산부가염을 유효 성분으로 하는 구강 건조증 치료제.
    (식중, R1및 R2는 동일하든지 다른 것이라도 좋고, 각각 수소, 알킬, 시클로벤틸, 아릴 또는 디아릴메틸롤 또는 하나 이상의 아릴기로 치환된 알킬이다.)
  2. 제1항에 있어서, 구강 건조증이 비세그렌증후성 구강 건조증 치료제.
  3. 제1항 또는 제2항에 있어서, 스피로옥사티올란퀴누클리딘 산부가염이 다음의 일반식(Ⅱ)로 표시되는 2-메틸스피로(1,3-옥사티올란-5,3′)퀴누클리딘염 산부가염인 구강 건조증 치료제.
  4. 제3항에 있어서, 2-메틸스피로(1,3-옥사티올란-5,3′)퀴누클리딘염 산부가염이 시스체인 구강 건조증 치료제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950015296A 1994-06-27 1995-06-10 비쇼그렌증후군성구강건조증치료제 KR100322042B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6168982A JP2852608B2 (ja) 1994-06-27 1994-06-27 口腔乾燥症治療剤
JP1994-168982 1994-06-27

Publications (2)

Publication Number Publication Date
KR960000222A true KR960000222A (ko) 1996-01-25
KR100322042B1 KR100322042B1 (ko) 2002-11-04

Family

ID=15878165

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950015296A KR100322042B1 (ko) 1994-06-27 1995-06-10 비쇼그렌증후군성구강건조증치료제

Country Status (15)

Country Link
US (1) US5580880A (ko)
EP (1) EP0689836B1 (ko)
JP (1) JP2852608B2 (ko)
KR (1) KR100322042B1 (ko)
AT (1) ATE205085T1 (ko)
AU (1) AU707236B2 (ko)
CA (1) CA2152420A1 (ko)
CY (1) CY2290B1 (ko)
DE (1) DE69522511T2 (ko)
DK (1) DK0689836T3 (ko)
ES (1) ES2163474T3 (ko)
IL (1) IL114256A (ko)
NO (1) NO309454B1 (ko)
TW (1) TW401298B (ko)
ZA (1) ZA955317B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618341D0 (en) * 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
JP4909809B2 (ja) * 1999-03-24 2012-04-04 生化学工業株式会社 人工唾液
WO2006013914A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 口腔粘膜投与剤
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US9161909B2 (en) * 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8450487B2 (en) 2010-06-08 2013-05-28 Apicore, Llc Process for the preparation of cis-2-methylspiro (1,3-oxathiolane 5-3′) quinuclidine
WO2017094910A1 (ja) 2015-12-04 2017-06-08 三栄源エフ・エフ・アイ株式会社 酵素処理イソクエルシトリンの利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US5078129A (en) * 1987-05-01 1992-01-07 Research Foundation Of State University Of New York Device for stimulating salivation
IL87234A (en) 1987-08-13 1992-02-16 Israel Inst Biolog Res Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
US4917674A (en) * 1988-04-04 1990-04-17 Molinoff Henry C Mouth moisturizing device
US4906455A (en) * 1988-04-15 1990-03-06 Wm. Wrigley Jr. Company Method for treating xerostomia employing chewing gum containing relatively insoluble, hydrophobic, food-grade organic acid
US4983378A (en) * 1988-11-22 1991-01-08 Parnell Pharmaceuticals, Inc. Method and composition for treating xerostomia
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
JP3018494B2 (ja) * 1990-11-30 2000-03-13 ソニー株式会社 特殊効果装置
JP2683783B2 (ja) * 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤

Also Published As

Publication number Publication date
JPH0812575A (ja) 1996-01-16
JP2852608B2 (ja) 1999-02-03
NO309454B1 (no) 2001-02-05
IL114256A0 (en) 1995-10-31
ATE205085T1 (de) 2001-09-15
EP0689836A1 (en) 1996-01-03
NO952561L (no) 1995-12-28
DE69522511D1 (de) 2001-10-11
ZA955317B (en) 1996-02-02
TW401298B (en) 2000-08-11
AU2324595A (en) 1996-01-11
ES2163474T3 (es) 2002-02-01
IL114256A (en) 1999-05-09
DE69522511T2 (de) 2002-05-16
CA2152420A1 (en) 1995-12-28
AU707236B2 (en) 1999-07-08
CY2290B1 (en) 2003-07-04
NO952561D0 (no) 1995-06-26
KR100322042B1 (ko) 2002-11-04
DK0689836T3 (da) 2002-05-06
US5580880A (en) 1996-12-03
EP0689836B1 (en) 2001-09-05

Similar Documents

Publication Publication Date Title
KR960000222A (ko) 구강 건조증 치료제
BE904421A (fr) Derives heterocycliques aromatiques et leur application dans les domaines therapeutique et cosmetique.
BR9702362A (pt) Novas fomrulações lìquidas estáveis à base de paracetamol e seu modo de preparação.
ATE79761T1 (de) Behandlung einer krankheit vom aids-typ.
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR970025615A (ko) 암 전이 억제제
KR880010770A (ko) 테트라하이드로벤즈[c,d]인돌-6-카복스아미드를 사용한 불안증 치료 방법
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
ES2037829T3 (es) Agentes contra el glaucoma a base de tiofen sulfonamida.
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
NO172043C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater
KR890003752A (ko) 2-피리미디닐-피페라딘 유도체의 용도
FR2362849A1 (fr) Nouvelles heterocyclo-omega-pentanorprostaglandines aryliques substituees en position 2 et medicament les contenant
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
KR880004810A (ko) 소화성 궤양 치료제
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
KR900016156A (ko) 퀴녹살린 유도체 및 궤양치료제
KR910015301A (ko) 수면 무호흡증의 치료방법
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR880001630A (ko) 5-플루오로우라실 유도체 및 그의 용도
KR890001555A (ko) 요산 배설용 조성물
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
KR890009397A (ko) 디하이드로피리딘 화합물을 함유하는 뇌뉴우론 보호제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20071227

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee